Inner Mongolia Furui Medical Science Co., Ltd.
福瑞医科
300049
Shenzhen Stock Exchange
Company Profile
Product and brand advantages： 1.Our product Compound Biejia Ruangan Tablets is the first anti-hepatic fibrosis drug approved by NMPA, a national patented product, and a prescription drug included in China's National Reimbursement Drug List. With more than 20 years of market validation, Ruangan Tablets has been recommended by 11 major medical associations and 14 guidelines, including the Chinese Society of Hepatology. as the preferred clinical pharmaceutical option for “softening liver” (ruangan); 2. Our FibroScan series, as the world's first clinically verified non-invasive real-time testing equipment that apply transient elastography to quantifying liver stiffness, have been certified by EU CE, FDA, and NMPA, etc., and have been listed in the guidelines for liver disease detection or officially recommended as liver elasticity testing equipment by a range of authoritative organizations including the World Health Organization (WHO) and American Association for the Study of Liver Diseases (AASLD). More than 3,500 peer-reviewed articles and 160 international guidelines have demonstrated the effectiveness of FibroScan in the diagnosis and treatment of liver diseases, indicating its important academic and market positions in the Global field of liver diseases. Research and Technological Advantages: Furui attaches great importance to the investment in product development and enhancement of our comprehensive development capabilities. We have been persistently engaged in the research and development of liver disease diagnosis technologies, in striving to develop more diversified and intelligent liver disease diagnostic series in response to market demands at various levels. Furui's hepatic fibrosis diagnostic series are the world's first clinically verified non-invasive real-time testing equipment that apply transient elastography to quantifying liver stiffness, providing advantages including accurate grading and no suffering from invasion while greatly reducing the examination cost for patients. Furthermore, Furui has successively released a localized FibroScan series, which, on the basis of maintaining consistent quality and technology level with the international standard, integrates the innovativeness and high standard of China's "intelligent manufacturing", making them more intelligent, user-friendly and convenient to use. Global Strategic Layout Advantages: Headquartered in Beijing, Furui operates subsidiaries all across Europe, the United States, Hong Kong and important provincial capitals in Chinese mainland, forming a strategic layout with Beijing as the headquarters, Paris as the R&D base, and business presence all over the world. Owing to a globalized sales network, we have been operating in medical devices in more than 100 countries or regions in the Asian-Pacific region, Europe, and North America. Advantages in full industry chain for liver diseases: Furui has been committed to the comprehensive management of liver diseases, covering the entire process from upstream liver disease diagnostic instruments, and therapeutic agents, as well as drug agency and delivery service, to the downstream processes including management and mutual insurance of patients with liver diseases, and liver disease big data, penetrating the whole life cycle including screening and diagnosis, therapeutic intervention, risk assessment, and health management. This has enabled us to provide comprehensive professional solutions for patients with liver diseases, and form the advantage of a complete strategic resource layout for the full industrial chain of liver disease diagnosis and treatment.
Full description
With the strategic goal of "integrating global resources to support the Healthy China strategy, and providing comprehensive, safe, effective, and convenient medical services throughout the entire healthcare cycle., Furui is is primarily involved in pharmaceutical production and sales, research and sales of diagnostic equipment, and related healthcare services. The company's flagship pharmaceutical product is the Compound Biejia Ruangan Tablets. is the first anti-fibrosis medication approved by the National Medical Products Administration (NMPA) in China. It holds a national patent and is listed as a prescription drug in the national medical insurance catalog. After over 20 years of market validation, The Tablets have become a well-known brand for anti-fibrosis treatment, enjoying wide market recognition. The company is continuously expanding its sales model, transitioning towards retail channels with independent pricing for drugs. This shift aims to increase revenue and improve profit margins in the pharmaceutical business while enhancing its risk resilience. Our key diagnostic products are the FibroScan series diagnostic instruments for hepatic fibrosis. This device utilizes advanced patented technologies such as VCTE-based LSM (liver stiffness measurement), SSM (spleen stiffness measurement), and CAP (controlled attenuation parameter).. easurement), and CAP (controlled attenuation parameter). It is capable of evaluating liver fibrosis, portal hypertension, and liver steatosis, and it is the world's first non-invasive and real-time detection equipment that quantifies liver stiffness using transient elastography. The FibroScan has obtained certifications such as CE (European Union), FDA (United States), and NMPA (China). It has been included in liver disease testing guidelines or recommended as an official liver elasticity testing device by authoritative organizations such as the World Health Organization (WHO) and the American Association for the Study of Liver Diseases (AASLD). The company aims to seize the development opportunities in the NASH (Nonalcoholic Steatohepatitis) field, expand the clinical applications of FibroScan, increase its usage in primary healthcare institutions and departments outside of hepatology, and promote its routine screening and diagnosis for the general population. The goal is to establish FibroScan as the global gold standard in non-invasive NASH diagnosis. In terms of pediatric healthcare services, Furui, adhering to the concept of "comprehensive lifecycle health management for children." It focuses on two key areas:1. Supporting accessible and inclusive public welfare sectors in the graded diagnosis and treatment, empowering primary healthcare institutions and doctors with basic medical and public health services. The company collaborates closely with medical institutions such as the Children's Hospital of Zhejiang University School of Medicine and the Pediatric Hospital affiliated with Fudan University. 2. Supporting profitable sectors in children's health consumption, such as pediatric health management and rehabilitation during special periods. The company has already opened three pediatric outpatient clinics in the Chengdu region. In the field of chronic liver disease management, the company assists hospitals nationwide in establishing comprehensive management centers. They implement a management-oriented medical model centered around "dual-therapy" combining antiviral and anti-fibrosis treatments. Together with hospitals, they provide "pay-for-performance" liver disease management services, covering pre-diagnosis, during-diagnosis, and post-diagnosis stages, aiming to improve treatment rates and patient compliance, reduce the occurrence of cirrhosis and liver cancer, and achieve a win-win situation for medical insurance, doctors, and patients.